BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

941 related articles for article (PubMed ID: 26282654)

  • 1. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
    Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
    J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.
    Perroud C; Thurian D; Andres M; Künzi A; Wiedemann G; Zeerleder S; Bacher U; Pabst T; Banz Y; Porret N; Rebmann E
    Hematol Oncol; 2023 Dec; 41(5):912-921. PubMed ID: 37452600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients.
    Hu Y; Chen W; Wang J
    Onco Targets Ther; 2019; 12():9999-10010. PubMed ID: 31819496
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Boyle EM; Ashby C; Tytarenko RG; Deshpande S; Wang H; Wang Y; Rosenthal A; Sawyer J; Tian E; Flynt E; Hoering A; Johnson SK; Rutherford MW; Wardell CP; Bauer MA; Dumontet C; Facon T; Thanendrarajan S; Schinke CD; Zangari M; van Rhee F; Barlogie B; Cairns D; Jackson G; Thakurta A; Davies FE; Morgan GJ; Walker BA
    Clin Cancer Res; 2020 May; 26(10):2422-2432. PubMed ID: 31988198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.
    Ryland GL; Jones K; Chin M; Markham J; Aydogan E; Kankanige Y; Caruso M; Guinto J; Dickinson M; Prince HM; Yong K; Blombery P
    J Clin Pathol; 2018 Oct; 71(10):895-899. PubMed ID: 29760015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
    Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
    Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
    Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies FE; Rosenthal A; Wang H; Qu P; Hoering A; Samur M; Towfic F; Ortiz M; Flynt E; Yu Z; Yang Z; Rozelle D; Obenauer J; Trotter M; Auclair D; Keats J; Bolli N; Fulciniti M; Szalat R; Moreau P; Durie B; Stewart AK; Goldschmidt H; Raab MS; Einsele H; Sonneveld P; San Miguel J; Lonial S; Jackson GH; Anderson KC; Avet-Loiseau H; Munshi N; Thakurta A; Morgan GJ
    Blood; 2018 Aug; 132(6):587-597. PubMed ID: 29884741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
    Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
    Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
    White BS; Lanc I; O'Neal J; Gupta H; Fulton RS; Schmidt H; Fronick C; Belter EA; Fiala M; King J; Ahmann GJ; DeRome M; Mardis ER; Vij R; DiPersio JF; Levy J; Auclair D; Tomasson MH
    Blood Cancer J; 2018 Mar; 8(3):35. PubMed ID: 29563506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
    Tessoulin B; Moreau-Aubry A; Descamps G; Gomez-Bougie P; Maïga S; Gaignard A; Chiron D; Ménoret E; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
    J Hematol Oncol; 2018 Dec; 11(1):137. PubMed ID: 30545397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.
    Bolli N; Li Y; Sathiaseelan V; Raine K; Jones D; Ganly P; Cocito F; Bignell G; Chapman MA; Sperling AS; Anderson KC; Avet-Loiseau H; Minvielle S; Campbell PJ; Munshi NC
    Blood Cancer J; 2016 Sep; 6(9):e467. PubMed ID: 27588520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
    Lohr JG; Stojanov P; Carter SL; Cruz-Gordillo P; Lawrence MS; Auclair D; Sougnez C; Knoechel B; Gould J; Saksena G; Cibulskis K; McKenna A; Chapman MA; Straussman R; Levy J; Perkins LM; Keats JJ; Schumacher SE; Rosenberg M; ; Getz G; Golub TR
    Cancer Cell; 2014 Jan; 25(1):91-101. PubMed ID: 24434212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population.
    Jirabanditsakul C; Dakeng S; Kunacheewa C; U-Pratya Y; Owattanapanich W
    Technol Cancer Res Treat; 2022; 21():15330338221111228. PubMed ID: 35770320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients.
    Cheung CHY; Cheng CK; Lau KM; Ip RKL; Chan NCN; Tam THC; Wong RSM; Raghupathy R; Chan NPH; Ng MHL
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e315-e325. PubMed ID: 29807803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients].
    Fan Y; Wang SJ; Liu YF; Wang C; Li YF; Wang WQ; Hao QQ; Zhang DF; Li YM; Sun H; Guo R; Chen SQ; Xie XS; Li T; Wan DM; Jiang ZX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):166-169. PubMed ID: 35123621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
    Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
    J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
    Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio W; Li B; Neuwirth R; Chattopadhyay N; Bolen JB; Dorner AJ; van de Velde H; Ricci D; Jagannath S; Berenson JR; Richardson PG; Stadtmauer EA; Orlowski RZ; Lonial S; Anderson KC; Sonneveld P; San Miguel JF; Esseltine DL; Schu M
    Blood; 2014 Jan; 123(5):632-9. PubMed ID: 24335104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.